About hospital-acquired infections
Hospital-acquired diseases are also known as nosocomial infections that are acquired in hospitals and other healthcare facilities. These infections are classified only when a patient is admitted for reasons other than the infections and are caused by bacteria, fungi, parasites, or viruses. Most common types of hospital-acquired infections are SSIs, UTIs, bloodstream infections, pneumococcal infections, MRSA, and gastrointestinal illnesses. These infections appear between 48 hours and four days after a patient is admitted and are usually related to a treatment of procedure used to treat or diagnose the patient's initial illness or injury. Hospital-acquired diseases are preventable through adherence to strict guidelines and less usage of invasive equipment that must be followed by healthcare professionals while caring for the patient. Anti-infective drugs are used for the treatment of these infections. These infections can be minimized by following proper infection control measures in the hospitals and healthcare institutions.
Technavio's analysts forecast the global hospital infection therapeutics market to grow at a CAGR of 3.24% over the period 2014-2019.
Covered in this report
The report covers the present scenario and growth prospects of the global hospital infection therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of drugs used in the treatment of various hospital-acquired infections such as bloodstream infections, Clostridium difficile infections, hospital-acquired pneumonia, surgical site infections, and urinary tract infections.
Technavio's report, Global Hospital Infection Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hospital infection therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Hospital Infection Therapeutics Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Hospital Infection Therapeutics Market: Allergan, Bayer, GlaxoSmithKline, Merck and Pfizer
Other Prominent Vendors in the market are: Abbott Laboratories, Achaogen, AmpliPhi Biosciences, Angelini Pharma, Aridis Pharmaceuticals, AstraZeneca, Durata Therapeutics, F. Hoffmann-La Roche, Isis Pharmaceuticals, Johnson & Johnson, Ligand Pharmaceuticals, Massachusetts Biological Laboratories, Medarex, Meiji Seika Pharma, Melinta Therapeutics, Nektar, Novartis, Prokarium, Sanofi, Tetraphase Pharmaceuticals, the Medicines Company, and Valneva.
Commenting on the report, an analyst from Technavio’s team said: “Patient assistance programs are expected to boost the growth of the market during the forecast period. Vendors provide co-pay assistance to individuals who purchase the indicated drugs for treating infections. Pfizer's drug Zyvox has a co-pay assistance program to provide financial assistance.”
According to the report, surgeries for cardiac, renal, and gastrointestinal disorders and cesarean section for childbirth are commonly performed currently. Many individuals also choose esthetic enhancement surgeries such as maxillofacial and prosthetic surgeries. This leads to increased exposure to microbes in the hospital environment, thus leading to infections and other complications. Surgeries increase the length of stay in the hospital and individuals are at greater risk of contracting infections.
Further, the report states that generic drugs are similar in quality, dosage form, strength, and efficacy to branded drugs, but are available at lower prices. A branded drug can be manufactured as generic after losing its patent. Many of the anti-infective drugs such as ceftriaxone, ampicillin, ampicillin and sulbactam, and ertapenem, are available as generics in the market.
Allergan, Bayer, GlaxoSmithKline, Merck, Pfizer, Abbott Laboratories, Achaogen, AmpliPhi Biosciences, Angelini Pharma, Aridis Pharmaceuticals, AstraZeneca, Durata Therapeutics, F. Hoffmann-La Roche, Isis Pharmaceuticals, Johnson & Johnson, Ligand Pharmaceuticals, Massachusetts Biological Laboratories, Medarex, Meiji Seika Pharma, Melinta Therapeutics, Nektar, Novartis, Prokarium, Sanofi, Tetraphase Pharmaceuticals, the Medicines Company, Valneva.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook